Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting

GlobeNewswire May 12, 2014

Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome

GlobeNewswire May 8, 2014

Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences

GlobeNewswire May 8, 2014

Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014

GlobeNewswire May 7, 2014

Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting

GlobeNewswire May 5, 2014

Alcobra Issued New US Patent Covering Metadoxine Use for Cognitive Disorders

GlobeNewswire May 1, 2014

Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings

GlobeNewswire April 24, 2014

Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome

GlobeNewswire April 10, 2014

Alcobra Announces Shares Uplisted to NASDAQ Global Market

GlobeNewswire March 26, 2014

Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD

GlobeNewswire March 18, 2014

Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)

GlobeNewswire March 6, 2014

Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference

GlobeNewswire February 24, 2014

Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer

GlobeNewswire February 19, 2014

Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update

GlobeNewswire February 13, 2014

Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD

GlobeNewswire February 7, 2014

Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference

Globe Newswire January 31, 2014

Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014

Globe Newswire January 29, 2014

Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI

Globe Newswire January 27, 2014

Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer

Globe Newswire January 13, 2014

Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors

Business Wire January 6, 2014